The “Connection” Between HIV Drug Resistance and RNase H

Currently, nucleoside reverse transcriptase inhibitors (NRTIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs) are two classes of antiretroviral agents that are approved for treatment of HIV-1 infection. Since both NRTIs and NNRTIs target the polymerase (pol) domain of reverse transcriptase (RT), most genotypic analysis for drug resistance is limited to the first ∼300 amino acids of RT. However, recent studies have demonstrated that mutations in the C-terminal domain of RT, specifically the connection subdomain and RNase H domain, can also increase resistance to both NRTIs and NNRTIs. In this review we will present the potential mechanisms by which mutations in the C-terminal domain of RT influence NRTI and NNRTI susceptibility, summarize the prevalence of the mutations in these regions of RT identified to date, and discuss their importance to clinical drug resistance.

• Publication year

  2010

• Venue

  Viruses

• Publication date

  2010-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3390/v2071476PMID 21088701PMCID 2982141
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 2022 update of the drug resistance mutations in HIV-1.

  2022cited by this paper
• The Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance

  2010cited by this paper
• Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase

  2010cited by this paper
• Connection Domain Mutations in Treatment-Experienced Patients in the OPTIMA Trial

  2010influential reference
• Drug-resistant mutation patterns in CRF01_AE cases that failed d4T+3TC+nevirapine fixed-dosed, combination treatment: Follow-up study from the Lampang cohort.

  2010cited by this paper
• Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase.

  2010cited by this paper
• A Novel Molecular Mechanism of Dual Resistance to Nucleoside and Nonnucleoside Reverse Transcriptase Inhibitors

  2010cited by this paper
• Molecular diversity and polymerase gene genotypes of HIV-1 among treatment-naïve Cameroonian subjects with advanced disease.

  2010cited by this paper
• Combinations of Mutations in the Connection Domain of Human Immunodeficiency Virus Type 1 Reverse Transcriptase: Assessing the Impact on Nucleoside and Nonnucleoside Reverse Transcriptase Inhibitor Resistance

  2010influential reference
• Positive and Negative drug Selection Pressures on the N348I Connection Domain Mutation: New Insights from in vivo Data

  2010cited by this paper
• N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations

  2010cited by this paper
• A single deletion at position 134, 135, or 136 in the beta 7–beta 8 loop of the p51 subunit of HIV‐1 RT disrupts the formation of heterodimeric enzyme

  2009cited by this paper
• Update of the drug resistance mutations in HIV-1: December 2009.

  2009cited by this paper
• Mutations in the thumb–connection and RNase H domain of HIV type-1 reverse transcriptase of antiretroviral treatment-experienced patients

  2009cited by this paper
• HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations

  2009influential reference
• Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition.

  2009cited by this paper
• Subtype-Specific Differences in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Connection Subdomain of CRF01_AE Are Associated with Higher Levels of Resistance to 3′-Azido-3′-Deoxythymidine

  2009cited by this paper
• Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naïve patients.

  2009cited by this paper
• Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants.

  2009cited by this paper
• Non-nucleoside HIV-1 reverse transcriptase inhibitors di-halo-indolyl aryl sulfones achieve tight binding to drug-resistant mutants by targeting the enzyme-substrate complex.

  2009influential reference
• HIV-1 reverse transcriptase connection subdomain mutations reduce template RNA degradation and enhance AZT excision

  2008cited by this paper
• Update of the Drug Resistance Mutations in HIV-1.

  2008cited by this paper
• Efavirenz Accelerates HIV-1 Reverse Transcriptase Ribonuclease H Cleavage, Leading to Diminished Zidovudine Excision

  2008influential reference
• Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.

  2008cited by this paper
• Mechanism by which a glutamine to leucine substitution at residue 509 in the ribonuclease H domain of HIV-1 reverse transcriptase confers zidovudine resistance.

  2008cited by this paper
• Impact of residues in the nonnucleoside reverse transcriptase inhibitor binding pocket on HIV-1 reverse transcriptase heterodimer stability.

  2008cited by this paper
• Conservation Patterns of HIV-1 RT Connection and RNase H Domains: Identification of New Mutations in NRTI-Treated Patients

  2008cited by this paper
• Connection Domain Mutations N348I and A360V in HIV-1 Reverse Transcriptase Enhance Resistance to 3′-Azido-3′-deoxythymidine through Both RNase H-dependent and -independent Mechanisms

  2008influential reference
• Selective targeting of the HIV-1 reverse transcriptase catalytic complex through interaction with the "primer grip" region by pyrrolobenzoxazepinone non-nucleoside inhibitors correlates with increased activity towards drug-resistant mutants.

  2008influential reference
• Amino Acid Mutation N348I in the Connection Subdomain of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confers Multiclass Resistance to Nucleoside and Nonnucleoside Reverse Transcriptase Inhibitors

  2008cited by this paper
• Mutations in Human Immunodeficiency Virus Type 1 RNase H Primer Grip Enhance 3′-Azido-3′-Deoxythymidine Resistance

  2007cited by this paper
• N348I in the Connection Domain of HIV-1 Reverse Transcriptase Confers Zidovudine and Nevirapine Resistance

  2007influential reference
• Substrate-dependent inhibition or stimulation of HIV RNase H activity by non-nucleoside reverse transcriptase inhibitors (NNRTIs).

  2007cited by this paper
• Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097.

  2007cited by this paper
• Mechanisms by Which the G333D Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Facilitates Dual Resistance to Zidovudine and Lamivudine

  2007cited by this paper
• Relationship between mutations in HIV‐1 RNase H domain and nucleoside reverse transcriptase inhibitors resistance mutations in naïve and pre‐treated HIV infected patients

  2007cited by this paper
• Selection of Mutations in the Connection and RNase H Domains of Human Immunodeficiency Virus Type 1 Reverse Transcriptase That Increase Resistance to 3′-Azido-3′-Dideoxythymidine

  2007cited by this paper
• Variations in Reverse Transcriptase and RNase H Domain Mutations in Human Immunodeficiency Virus Type 1 Clinical Isolates Are Associated with Divergent Phenotypic Resistance to Zidovudine

  2007cited by this paper
• Identification of accessory mutations associated with high-level resistance in HIV-1 reverse transcriptase

  2007cited by this paper
• Relationship of potency and resilience to drug resistant mutations for GW420867X revealed by crystal structures of inhibitor complexes for wild-type, Leu100Ile, Lys101Glu, and Tyr188Cys mutant HIV-1 reverse transcriptases.

  2007cited by this paper
• Analysis of amino acids in the beta7-beta8 loop of human immunodeficiency virus type 1 reverse transcriptase for their role in virus replication.

  2007cited by this paper
• Mutations in the connection domain of HIV-1 reverse transcriptase increase 3′-azido-3′-deoxythymidine resistance

  2007cited by this paper
• Novel drug resistance mutations in HIV: recognition and clinical relevance.

  2006cited by this paper
• Combining mutations in HIV-1 reverse transcriptase with mutations in the HIV-1 polypurine tract affects RNase H cleavages involved in PPT utilization.

  2006cited by this paper
• Identification of amino acid residues in the human immunodeficiency virus type-1 reverse transcriptase tryptophan-repeat motif that are required for subunit interaction using infectious virions.

  2005cited by this paper
• Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision.

  2005cited by this paper
• Intracellular Substrates for the Primer-Unblocking Reaction by Human Immunodeficiency Virus Type 1 Reverse Transcriptase: Detection and Quantitation in Extracts from Quiescent- and Activated-Lymphocyte Subpopulations

  2005cited by this paper
• Dissecting the effects of DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reverse-transcriptase activities.

  2005cited by this paper
• From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase.

  2005cited by this paper
• From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase.

  2005cited by this paper
• The L74V Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Counteracts Enhanced Excision of Zidovudine Monophosphate Associated with Thymidine Analog Resistance Mutations

  2005cited by this paper
• HIV-1 resistance to dideoxynucleoside reverse transcriptase inhibitors: genotypic-phenotypic correlations.

  2004cited by this paper
• A Loss of Viral Replicative Capacity Correlates with Altered DNA Polymerization Kinetics by the Human Immunodeficiency Virus Reverse Transcriptase Bearing the K65R and L74V Dideoxynucleoside Resistance Substitutions*

  2004cited by this paper
• Antiretroviral Drug Resistance Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Increase Template-Switching Frequency

  2004cited by this paper
• Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure

  2004cited by this paper
• Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors.

  2004cited by this paper
• Mutation of Amino Acids in the Connection Domain of Human Immunodeficiency Virus Type 1 Reverse Transcriptase That Contact the Template-Primer Affects RNase H Activity

  2003cited by this paper
• The effect of NNRTIs on HIV reverse transcriptase dimerization.

  2003cited by this paper
• ATP-Dependent Removal of Nucleoside Reverse Transcriptase Inhibitors by Human Immunodeficiency Virus Type 1 Reverse Transcriptase

  2002cited by this paper
• Y586F mutation in murine leukemia virus reverse transcriptase decreases fidelity of DNA synthesis in regions associated with adenine–thymine tracts

  2002cited by this paper
• The M184V Mutation Reduces the Selective Excision of Zidovudine 5′-Monophosphate (AZTMP) by the Reverse Transcriptase of Human Immunodeficiency Virus Type 1

  2002cited by this paper
• Structures of HIV‐1 reverse transcriptase with pre‐ and post‐translocation AZTMP‐terminated DNA

  2002cited by this paper
• A Mutation in the 3′ Region of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase (Y318F) Associated with Nonnucleoside Reverse Transcriptase Inhibitor Resistance

  2002cited by this paper
• Effects of Specific Zidovudine Resistance Mutations and Substrate Structure on Nucleotide-Dependent Primer Unblocking by Human Immunodeficiency Virus Type 1 Reverse Transcriptase

  2002cited by this paper
• Altering the RNase H primer grip of human immunodeficiency virus reverse transcriptase modifies cleavage specificity.

  2002cited by this paper
• Mutational Analysis of Tyr-501 of HIV-1 Reverse Transcriptase

  2002cited by this paper
• Mutations in the RNase H domain of HIV-1 reverse transcriptase affect the initiation of DNA synthesis and the specificity of RNase H cleavage in vivo

  2002cited by this paper
• Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase

  2001cited by this paper
• Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors.

  2001cited by this paper
• Crystal structure of HIV‐1 reverse transcriptase in complex with a polypurine tract RNA:DNA

  2001cited by this paper
• The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance.

  2001cited by this paper
• Selective Excision of AZTMP by Drug-Resistant Human Immunodeficiency Virus Reverse Transcriptase

  2001cited by this paper
• Increased Drug Susceptibility of HIV-1 Reverse Transcriptase Mutants Containing M184V and Zidovudine-Associated Mutations: Analysis of Enzyme Processivity, Chain-Terminator Removal and Viral Replication

  2000cited by this paper
• Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine.

  2000cited by this paper
• The M184V Mutation in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 Impairs Rescue of Chain-Terminated DNA Synthesis

  2000cited by this paper
• Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids.

  1999cited by this paper
• Mutation Patterns of the Reverse Transcriptase and Protease Genes in Human Immunodeficiency Virus Type 1-Infected Patients Undergoing Combination Therapy: Survey of 787 Sequences

  1999cited by this paper
• A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase.

  1999cited by this paper
• Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase.

  1999cited by this paper
• Sarafianos, S.G. et al. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with -branched amino acids. Proc. Natl. Acad. Sci. USA 96, 10027-10032

  1999cited by this paper
• Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance.

  1998cited by this paper
• Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 A resolution.

  1998cited by this paper
• Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase.

  1998cited by this paper
• Interaction of retroviral reverse transcriptase with template-primer duplexes during replication.

  1998cited by this paper
• The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.

  1998cited by this paper
• Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance.

  1998cited by this paper
• A Novel Polymorphism at Codon 333 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Can Facilitate Dual Resistance to Zidovudine and l-2′,3′-Dideoxy-3′-Thiacytidine

  1998influential reference
• Mutational Analysis of Tyr-318 within the Non-nucleoside Reverse Transcriptase Inhibitor Binding Pocket of Human Immunodeficiency Virus Type I Reverse Transcriptase*

  1998cited by this paper
• Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism.

  1998cited by this paper
• Protein-nucleic acid interactions and DNA conformation in a complex of human immunodeficiency virus type 1 reverse transcriptase with a double-stranded DNA template-primer.

  1997cited by this paper
• Reverse Transcriptase and the Generation of Retroviral DNA

  1997cited by this paper
• Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3-TC.

  1997cited by this paper
• Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions.

  1997cited by this paper
• Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant.

  1996cited by this paper
• Selection in vitro of an HIV-1 variant resistant to both lamivudine (3TC) and zidovudine.

  1996cited by this paper
• HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors.

  1996cited by this paper
• High resolution structures of HIV-1 RT from four RT–inhibitor complexes

  1995cited by this paper
• Nevirapine Alters the Cleavage Specificity of Ribonuclease H of Human Immunodeficiency Virus 1 Reverse Transcriptase (*)

  1995cited by this paper
• Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors

  1995cited by this paper
• Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1.

  1994cited by this paper

• Noncanonical HIV drug resistance mutations: need to close existing gaps

  2025cites this paper
• Global hinge sites of proteins as target sites for drug binding

  2024cites this paper
• Evaluation of HIV-1 antiretroviral drug resistance profiles in the peripheral blood reservoir of successfully treated persons using massive sequencing and viral full genome characterization.

  2023cites this paper
• Resistance Trends of Antiretroviral Agents in People with Human Immunodeficiency Virus in Korea, 2012 - 2020

  2023cites this paper
• DiMA: sequence diversity dynamics analyser for viruses

  2022cites this paper
• Analysis and Molecular Determinants of HIV RNase H Cleavage Specificity at the PPT/U3 Junction

  2021cites this paper
• Discordance between Etravirine Phenotype and Genotype-Based Predicted Phenotype for Subtype C HIV-1 from First-Line Antiretroviral Therapy Failures in South Africa

  2020cites this paper
• Cyclodextrin supramolecular inclusion-enhanced pyrene excimer switching for highly selective detection of RNase H.

  2019cites this paper
• Explore the Novel Biomarkers through Next-Generation Sequencing

  2018cites this paper
• The HIV-1 reverse transcriptase E138A natural polymorphism decreases the genetic barrier to resistance to etravirine in vitro

  2018cites this paper
• Resistance Mechanisms to HIV-1 Nucleoside Reverse Transcriptase Inhibitors

  2017cites this paper
• Characterization of HIV-1 Near Full-Length Proviral Genome Quasispecies from Patients with Undetectable Viral Load Undergoing First-Line HAART Therapy

  2017cites this paper
• Control of Bacterial Growth Through RNA Degradation

  2016cites this paper
• HIV-1 Protease, Reverse Transcriptase, and Integrase Variation

  2016cites this paper
• Characterizing protease inhibitor failure in HIV-1 subtype C, using ultra deep pyro-sequencing and homology modelling.

  2015cites this paper
• Effects of HIV-1 reverse transcriptase connection subdomain mutations on polypurine tract removal and initiation of (+)-strand DNA synthesis

  2015cites this paper
• A novel mutation, D404N, in the connection subdomain of reverse transcriptase of HIV-1 CRF08_BC subtype confers cross-resistance to NNRTIs.

  2015cites this paper
• Multiple invasions of an infectious retrovirus in cat genomes

  2015cites this paper
• Inhibitors Rilpivirine and Etravirine Nonnucleoside Reverse Transcriptase Defining Patterns of Resistance to Interactions with the M184I Mutation on HIV-1 Reverse Transcriptase and Their Effect of Mutations at Position E138 in

  2014cites this paper
• Effects of the protonation state in the interaction of an HIV-1 reverse transcriptase (RT) amino acid, Lys101, and a non nucleoside RT inhibitor, GW420867X

  2014cites this paper
• Drug Resistance in Non-B Subtype HIV-1: Impact of HIV-1 Reverse Transcriptase Inhibitors

  2014cites this paper
• Real time monitoring of junction ribonuclease activity of RNase H using chimeric molecular beacons.

  2013cites this paper
• Biophysical Insights into the Inhibitory Mechanism of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors

  2013cites this paper
• Complexes of HIV-1 RT, NNRTI and RNA/DNA hybrid reveal a structure compatible with RNA degradation

  2013cites this paper
• The Effect of Mutations at Position E 138 in HIV-1 Reverse Transcriptase and their Interactions 1 with the M 184 I Mutation in Defining Patterns of Resistance to the Non-Nucleoside Reverse 2 Transcriptase Inhibitors

  2013cites this paper
• A Polymorphism at Position 400 in the Connection Subdomain of HIV-1 Reverse Transcriptase Affects Sensitivity to NNRTIs and RNaseH Activity

  2013cites this paper
• Effect of Mutations at Position E138 in HIV-1 Reverse Transcriptase and Their Interactions with the M184I Mutation on Defining Patterns of Resistance to Nonnucleoside Reverse Transcriptase Inhibitors Rilpivirine and Etravirine

  2013cites this paper
• Connection subdomain mutations in HIV-1 subtype-C treatment-experienced patients enhance NRTI and NNRTI drug resistance.

  2013cites this paper
• Investigating the development and evolution of drug resistance in the HIV-1 pol gene

  2013influential citation
• Ribonuclease H Inhibitors: Structural and Molecular Biology

  2013cites this paper
• Nucleoside RT Inhibitors: Structural and Molecular Biology

  2013cites this paper
• Mechanistic insights into the role of secondary mutations of HIV-1 reverse transcriptase in the acquisition of antiretroviral drug resistance

  2013cites this paper
• An in‐house HIV genotyping assay for the detection of drug resistance mutations in Southeast Asian patients infected with HIV‐1

  2012cites this paper
• Frequent Emergence of N 348 I in HIV-1 Subtype C Reverse Transcriptase with Failure of Initial Therapy Reduces Susceptibility to Reverse-Transcriptase Inhibitors

  2012cites this paper
• A Role of Template Cleavage in Reduced Excision of Chain-Terminating Nucleotides by Human Immunodeficiency Virus Type 1 Reverse Transcriptase Containing the M184V Mutation

  2012cites this paper
• Screening for and Verification of Novel Mutations Associated with Drug Resistance in the HIV Type 1subtype B′ in China

  2012cites this paper
• HIV-1 Reverse Transcriptase Still Remains a New Drug Target: Structure, Function, Classical Inhibitors, and New Inhibitors with Innovative Mechanisms of Actions

  2012cites this paper
• HIV-1 Reverse Transcriptase (RT) Polymorphism 172K Suppresses the Effect of Clinically Relevant Drug Resistance Mutations to Both Nucleoside and Non-nucleoside RT Inhibitors*

  2012cites this paper
• Anti-human immunodeficiency virus type 1 activity of novel 6-substituted 1-3 benzyl-3-( 3 , 5-dimethylbenzyl ) uracil derivatives 4 5 Running title : Anti-HIV-1 activity of novel uracil derivatives 6 7

  2012cites this paper
• Anti-Human Immunodeficiency Virus Type 1 Activity of Novel 6-Substituted 1-Benzyl-3-(3,5-Dimethylbenzyl)Uracil Derivatives

  2012cites this paper
• Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors.

  2012cites this paper
• Drug resistance in HIV-1.

  2011cites this paper
• The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains

  2011cites this paper
• Phenotypic characterization of drug resistance-associated mutations in HIV-1 RT connection and RNase H domains and their correlation with thymidine analogue mutations.

  2011cites this paper
• Structure and Function of RNase H Enzymes

  2011cites this paper
• HIV-1 reverse transcriptase connection subdomain mutations involved in resistance to approved non-nucleoside inhibitors.

  2011cites this paper
• The Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance

  2010cites this paper
• Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C

  2010cites this paper